[go: up one dir, main page]

ES2428843T8 - Diagnóstico por la imagen de perfusión miocárdica utilizando agonistas del receptor de adenosina - Google Patents

Diagnóstico por la imagen de perfusión miocárdica utilizando agonistas del receptor de adenosina Download PDF

Info

Publication number
ES2428843T8
ES2428843T8 ES10011221T ES10011221T ES2428843T8 ES 2428843 T8 ES2428843 T8 ES 2428843T8 ES 10011221 T ES10011221 T ES 10011221T ES 10011221 T ES10011221 T ES 10011221T ES 2428843 T8 ES2428843 T8 ES 2428843T8
Authority
ES
Spain
Prior art keywords
receptor agonists
diagnostic imaging
adenosine receptor
myocardial perfusion
perfusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10011221T
Other languages
English (en)
Other versions
ES2428843T3 (es
Inventor
Luiz Belardinelli
Mitchell Rosner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Gilead Palo Alto Inc
Original Assignee
Gilead Sciences Inc
Gilead Palo Alto Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Gilead Palo Alto Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ES2428843T3 publication Critical patent/ES2428843T3/es
Publication of ES2428843T8 publication Critical patent/ES2428843T8/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
ES10011221T 2004-01-27 2004-01-27 Diagnóstico por la imagen de perfusión miocárdica utilizando agonistas del receptor de adenosina Expired - Lifetime ES2428843T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/002304 WO2005082379A1 (en) 2004-01-27 2004-01-27 Myocardial perfusion imaging using adenosine receptor agonists

Publications (2)

Publication Number Publication Date
ES2428843T3 ES2428843T3 (es) 2013-11-11
ES2428843T8 true ES2428843T8 (es) 2013-12-26

Family

ID=34912870

Family Applications (2)

Application Number Title Priority Date Filing Date
ES04705715T Expired - Lifetime ES2426913T3 (es) 2004-01-27 2004-01-27 Detección por la imagen de perfusión miocárdica utilizando agonistas del receptor de adenosina
ES10011221T Expired - Lifetime ES2428843T3 (es) 2004-01-27 2004-01-27 Diagnóstico por la imagen de perfusión miocárdica utilizando agonistas del receptor de adenosina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES04705715T Expired - Lifetime ES2426913T3 (es) 2004-01-27 2004-01-27 Detección por la imagen de perfusión miocárdica utilizando agonistas del receptor de adenosina

Country Status (15)

Country Link
EP (2) EP2366396B1 (es)
JP (1) JP4818127B2 (es)
KR (1) KR101143826B1 (es)
CN (1) CN1905887A (es)
AU (1) AU2004316372B2 (es)
CA (2) CA2554169C (es)
CY (2) CY1114928T1 (es)
DK (2) DK2366396T3 (es)
ES (2) ES2426913T3 (es)
IL (1) IL177119A (es)
NO (1) NO337132B1 (es)
NZ (1) NZ548794A (es)
PT (2) PT2366396E (es)
SI (2) SI1708721T1 (es)
WO (1) WO2005082379A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
WO2001062979A2 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Dentification of partial agonists of the a2a adenosine receptor
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
JP2005538190A (ja) 2002-07-29 2005-12-15 シーブイ・セラピューティクス・インコーポレイテッド 心筋潅流イメージング
RU2007114908A (ru) 2004-10-20 2008-10-27 Си Ви ТЕРАПЬЮСи Ви ТЕРАПЬЮТИКСИКС Применение агонистов аденозиновых рецепторов a2a
CA2640089C (en) 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
CA2716501A1 (en) * 2008-02-29 2009-09-03 King Pharmaceuticals Research And Development, Inc. Crystal forms of 2-{2-[(cyclohexyl)methylene]hydrazino}adenosine
RU2011115815A (ru) * 2008-09-29 2012-11-10 Гайлид Сайэнсиз, Инк. (Us) Комбинации средства, регулирующего частоту сердечных сокращений и агониста а-2-альфа рецепторов для применения в способах мультидетекторной компьютерной томографии
JP2011098990A (ja) * 2011-02-21 2011-05-19 Gilead Palo Alto Inc アデノシン受容体作動薬を使用する心筋灌流イメージング方法
RU2502461C1 (ru) * 2012-06-04 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "РКНПК" Минздравсоцразвития России) Способ диагностики ишемии миокарда у больных кардиальным синдромом х
US20190240247A1 (en) * 2016-09-01 2019-08-08 Leiutis Pharmaceuticals Pvt. Ltd. Pharmaceutical formulations of regadenoson

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6026317A (en) * 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
WO2001062979A2 (en) * 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Dentification of partial agonists of the a2a adenosine receptor
JP2005538190A (ja) * 2002-07-29 2005-12-15 シーブイ・セラピューティクス・インコーポレイテッド 心筋潅流イメージング

Also Published As

Publication number Publication date
SI1708721T1 (sl) 2013-10-30
SI2366396T1 (sl) 2013-10-30
EP1708721B1 (en) 2013-08-07
PT1708721E (pt) 2013-10-02
PT2366396E (pt) 2013-10-03
KR101143826B1 (ko) 2012-05-11
ES2426913T8 (es) 2013-12-16
EP1708721A1 (en) 2006-10-11
NO337132B1 (no) 2016-01-25
ES2428843T3 (es) 2013-11-11
IL177119A (en) 2011-07-31
DK2366396T3 (da) 2013-09-08
CY1114928T1 (el) 2016-12-14
EP2366396A1 (en) 2011-09-21
CA2691611A1 (en) 2005-09-09
JP2007519718A (ja) 2007-07-19
AU2004316372B2 (en) 2011-05-12
EP2366396B1 (en) 2013-08-07
NO20063629L (no) 2006-10-26
JP4818127B2 (ja) 2011-11-16
WO2005082379A8 (en) 2006-01-19
NZ548794A (en) 2009-07-31
DK1708721T3 (da) 2013-09-08
HK1162139A1 (en) 2012-08-24
WO2005082379A1 (en) 2005-09-09
ES2426913T3 (es) 2013-10-25
CY1115926T1 (el) 2017-01-25
CN1905887A (zh) 2007-01-31
KR20060130630A (ko) 2006-12-19
CA2554169C (en) 2010-03-16
IL177119A0 (en) 2008-03-20
CA2554169A1 (en) 2005-09-09
AU2004316372A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
ES2428843T8 (es) Diagnóstico por la imagen de perfusión miocárdica utilizando agonistas del receptor de adenosina
EP1746885A4 (en) AGONISTS OF A2A ADENOSINE RECEPTORS FOR THE TREATMENT OF NEEDLE INJURY IN DIABETES
EP2276469A4 (en) ALPHA-ADRENERGE RECEPTOR AGONISTS FOR THE TREATMENT OF BANDAGE DISEASE DISEASE DISEASES
IL228097A0 (en) Contrast agents for myocardial perfusion imaging
ATE502040T1 (de) Bisadenosinverbindungen als adenosin-a2a- rezeptoragonisten
ATE481404T1 (de) Adenosinderivate als agonisten am a2a-rezeptor
BRPI0923815A2 (pt) Síntese de nucleosídeos de purina
EP2213239A4 (en) ULTRASONIC IMAGING DEVICE
FI20065267L (fi) Järjestely dentaalikuvausta varten
BRPI0815097A2 (pt) agonistas de receptor acoplado à proteína g gpr119 de piridona
ZA200703229B (en) Use of A2A adenosine receptor agonists
ATE549350T1 (de) Neuropeptid-2-rezeptor-agonisten
IT1398643B1 (it) Composizione solida per la somministrazione orale di coloranti, e utilizzo diagnostico della stessa
EP2198292A4 (en) IMPROVED MORBUS ALZHEIMER DIAGNOSIS
WO2008075040A3 (en) Radioactive pet agents for imaging ccr5 in vivo
EP2171478A4 (en) IN VIVO IMAGING METHOD FOR SULPHOTRANSFERASES
DK2194993T3 (da) Fremgangsmåder til screening af lægemidler ved hjælp af non-invasiv in-vivo billeddannelse
ZA200702843B (en) Compounds for myocardial perfusion imaging
EP2198040A4 (en) IN VIVO FIGURE OF MYELIN
CR10703A (es) Derivados de silicio para obtencion de imagenes por tomografia de emision de positrones(pet)
EP2141230A4 (en) FLUORESCENCE-MARKED FUSION PROTEIN FOR TESTING ADENOSINTRIPHOSPHATE
IT1393062B1 (it) Procedimento per la preparazione di gemcitabina cloridrato
Fernandez-Tejada et al. Insights into the geometrical features underlying beta-O-GlcNAc glycosylation: water pockets drastically modulate the interactions between the carbohydrate and the peptide backbone
EP1845102A4 (en) Novel pyrimidine nucleoside compound or its salt
DE602008002293D1 (de) Ultraschallbildgebungsvorrichtung